These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 15224083)

  • 1. Polymorphism in candidate genes: implications for the risk and treatment of idiopathic Parkinson's disease.
    Gilgun-Sherki Y; Djaldetti R; Melamed E; Offen D
    Pharmacogenomics J; 2004; 4(5):291-306. PubMed ID: 15224083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The association of functional catechol-O-methyltransferase haplotypes with risk of Parkinson's disease, levodopa treatment response, and complications.
    Bialecka M; Kurzawski M; Klodowska-Duda G; Opala G; Tan EK; Drozdzik M
    Pharmacogenet Genomics; 2008 Sep; 18(9):815-21. PubMed ID: 18698234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genotype and smoking history affect risk of levodopa-induced dyskinesias in Parkinson's disease.
    Strong JA; Dalvi A; Revilla FJ; Sahay A; Samaha FJ; Welge JA; Gong J; Gartner M; Yue X; Yu L
    Mov Disord; 2006 May; 21(5):654-9. PubMed ID: 16435402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic polymorphism of the angiotensin converting enzyme and L-dopa-induced adverse effects in Parkinson's disease.
    Lin JJ; Yueh KC; Lin SZ; Harn HJ; Liu JT
    J Neurol Sci; 2007 Jan; 252(2):130-4. PubMed ID: 17196621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of monoamine oxidase B (MAOB) and catechol-O-methyltransferase (COMT) polymorphisms on levodopa therapy in patients with sporadic Parkinson's disease.
    Białecka M; Droździk M; Kłodowska-Duda G; Honczarenko K; Gawrońska-Szklarz B; Opala G; Stankiewicz J
    Acta Neurol Scand; 2004 Oct; 110(4):260-6. PubMed ID: 15355491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic polymorphism of Angiotensin-Converting Enzyme is not associated with the development of Parkinson's disease and of L-dopa-induced adverse effects.
    Pascale E; Purcaro C; Passarelli E; Guglielmi R; Vestri AR; Passarelli F; Meco G
    J Neurol Sci; 2009 Jan; 276(1-2):18-21. PubMed ID: 18805557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk factors in development of motor complications in Chinese patients with idiopathic Parkinson's disease.
    Kum WF; Gao J; Durairajan SS; Man SC; Xie LX; Lu JH; Fong WL; Li M
    J Clin Neurosci; 2009 Aug; 16(8):1034-7. PubMed ID: 19428256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 5,10-methylenetetrahydrofolate reductase C677T gene polymorphism can influence age at onset of Parkinson's disease.
    Lin JJ; Yueh KC; Liu CS; Liu JT; Lin SZ
    Acta Neurol Taiwan; 2007 Sep; 16(3):150-7. PubMed ID: 17966954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Motor complications in patients form the German Competence Network on Parkinson's disease and the DRD3 Ser9Gly polymorphism.
    Paus S; Gadow F; Knapp M; Klein C; Klockgether T; Wüllner U
    Mov Disord; 2009 May; 24(7):1080-4. PubMed ID: 19353703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The DRD2 TaqIA polymorphism and demand of dopaminergic medication in Parkinson's disease.
    Paus S; Grünewald A; Klein C; Knapp M; Zimprich A; Janetzky B; Möller JC; Klockgether T; Wüllner U
    Mov Disord; 2008 Mar; 23(4):599-602. PubMed ID: 18175338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sex differences in clinical and genetic determinants of levodopa peak-dose dyskinesias in Parkinson disease: an exploratory study.
    Zappia M; Annesi G; Nicoletti G; Arabia G; Annesi F; Messina D; Pugliese P; Spadafora P; Tarantino P; Carrideo S; Civitelli D; De Marco EV; Cirò-Candiano IC; Gambardella A; Quattrone A
    Arch Neurol; 2005 Apr; 62(4):601-5. PubMed ID: 15824260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose treatment with pergolide in Parkinson's disease patients with motor fluctuations and dyskinesias.
    Storch A; Trenkwalder C; Oehlwein C; Winkelmann J; Polzer U; Hundemer HP; Schwarz J
    Parkinsonism Relat Disord; 2005 Sep; 11(6):393-8. PubMed ID: 15993640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
    Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
    Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dopamine receptor gene polymorphisms in Parkinson's disease patients reporting "sleep attacks".
    Rissling I; Geller F; Bandmann O; Stiasny-Kolster K; Körner Y; Meindorfner C; Krüger HP; Oertel WH; Möller JC
    Mov Disord; 2004 Nov; 19(11):1279-84. PubMed ID: 15390060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ropinirole therapy for Parkinson's disease.
    Pahwa R; Lyons KE; Hauser RA
    Expert Rev Neurother; 2004 Jul; 4(4):581-8. PubMed ID: 15853577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Reconsiderations in the treatment of Parkinson's disease with levodopa: some pharmacodynamic evidence].
    Zappia M; Nicoletti A; Muñoz-S D; Tapia-Núñez J
    Rev Neurol; 2009 Jul 1-15; 49(1):33-40. PubMed ID: 19557698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Levodopa treatment does not affect low-dose apomorphine test in patients with Parkinson's disease.
    Happe S; Tings T; Helmschmied K; Neubert K; Wuttke W; Paulus W; Trenkwalder C
    Mov Disord; 2004 Dec; 19(12):1511-5. PubMed ID: 15390061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hyperhomocysteinemia and methylenetetrahydrofolate reductase polymorphism in patients with Parkinson's disease.
    Religa D; Czyzewski K; Styczynska M; Peplonska B; Lokk J; Chodakowska-Zebrowska M; Stepien K; Winblad B; Barcikowska M
    Neurosci Lett; 2006 Aug; 404(1-2):56-60. PubMed ID: 16787708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Early treatment of Parkinson's disease with levodopa].
    Odekerken VJ; Post B; Verschuur CV; de Bie RM
    Ned Tijdschr Geneeskd; 2009; 153():A286. PubMed ID: 19785822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial.
    Holloway RG; Shoulson I; Fahn S; Kieburtz K; Lang A; Marek K; McDermott M; Seibyl J; Weiner W; Musch B; Kamp C; Welsh M; Shinaman A; Pahwa R; Barclay L; Hubble J; LeWitt P; Miyasaki J; Suchowersky O; Stacy M; Russell DS; Ford B; Hammerstad J; Riley D; Standaert D; Wooten F; Factor S; Jankovic J; Atassi F; Kurlan R; Panisset M; Rajput A; Rodnitzky R; Shults C; Petsinger G; Waters C; Pfeiffer R; Biglan K; Borchert L; Montgomery A; Sutherland L; Weeks C; DeAngelis M; Sime E; Wood S; Pantella C; Harrigan M; Fussell B; Dillon S; Alexander-Brown B; Rainey P; Tennis M; Rost-Ruffner E; Brown D; Evans S; Berry D; Hall J; Shirley T; Dobson J; Fontaine D; Pfeiffer B; Brocht A; Bennett S; Daigneault S; Hodgeman K; O'Connell C; Ross T; Richard K; Watts A;
    Arch Neurol; 2004 Jul; 61(7):1044-53. PubMed ID: 15262734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.